KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNTech SE (BNTX) Total Liabilities (2018 - 2025)

BioNTech SE's Total Liabilities history spans 8 years, with the latest figure at $3.2 billion for Q4 2025.

  • On a quarterly basis, Total Liabilities fell 3.44% to $3.2 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $3.2 billion, a 3.44% decrease, with the full-year FY2025 number at $3.1 billion, down 6.28% from a year prior.
  • Total Liabilities hit $3.2 billion in Q4 2025 for BioNTech SE, down from $3.3 billion in the prior quarter.
  • Over the last five years, Total Liabilities for BNTX hit a ceiling of $6.5 billion in Q3 2021 and a floor of $7.0 million in Q4 2021.
  • Historically, Total Liabilities has averaged $3.3 billion across 5 years, with a median of $3.3 billion in 2022.
  • Biggest five-year swings in Total Liabilities: plummeted 99.38% in 2021 and later skyrocketed 47029.01% in 2022.
  • Tracing BNTX's Total Liabilities over 5 years: stood at $7.0 million in 2021, then skyrocketed by 47029.01% to $3.3 billion in 2022, then decreased by 9.69% to $3.0 billion in 2023, then rose by 12.21% to $3.3 billion in 2024, then decreased by 3.44% to $3.2 billion in 2025.
  • Business Quant data shows Total Liabilities for BNTX at $3.2 billion in Q4 2025, $3.3 billion in Q3 2025, and $3.5 billion in Q2 2025.